Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Post by need2stockupon Feb 28, 2012 10:08pm
465 Views
Post# 19602062

What's up with Synera?

What's up with Synera?

Did you know that Endo Pharmaceuticals first marketed Synera back in 2007. It didn't go so well. This blog states the following....

The main problem is that you really NEED 30 minutes for Synera to work well. This means that generic lidocaine cream, which can be purchased by the parent OTC works just as fast. The only thing we have to sell with is less blanching and less mess, more convenient in hospital. It is hard to convince pharmacy it is worth the 63% price increase for that. It is a neverending battle every day - Depodur or not....

Also according to Endo from their 2009 SEC filing they stated the following....

During the year ended December 31, 2007, as a result of the continued lack of commercial success of Synera™, we recorded an impairment charge of
.9 million related to the remaining unamortized portion of our ZARS intangible asset.

Now Nuvo/Zars are relaunching Synera in the USA. Are we beating a dead horse? We must have 21 of the best sales people in the world and our incentive program is better then everyone elses. Second time around will surely be better and we will break sales records. Can't wait. Need2.
 

Bullboard Posts